AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18094272 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol 320
Number of subjects: 72
Study 18094272 — intervention group
Group type: COMPARATOR
Intervention: iohexol 350
Number of subjects: 72
Study 16418022 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block with 0.75% ropivacaine administered before surgery (PRE group)
Number of subjects: 111
Study 16418022 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral superficial cervical plexus block with 0.75% ropivacaine administered after surgery (POST group)
Number of subjects: 111
Study 16418022 — intervention group
Group type: COMPARATOR
Intervention: No intervention (CONT group)
Number of subjects: 111
Study 12628531 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 36
Study 12628531 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone
Number of subjects: 36
Study 10693082 — intervention group
Group type: EXPERIMENTAL
Intervention: Newborns from Las Vegas (exposed to perchlorate)
Number of subjects: 23000
Study 10693082 — intervention group
Group type: COMPARATOR
Intervention: Newborns from Reno (not exposed to perchlorate)
Number of subjects: 23000
Study 10693082 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal differences in mean T4 levels in both cities
Number of subjects: 23000
Study 10693082 — intervention group
Group type: EXPERIMENTAL
Intervention: Effects of gender, birth weight, and day of life
Number of subjects: 23000
Study 10693082 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental exposures to perchlorate (up to 15 micrograms/L)
Number of subjects: 23000
Study 9465587 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT combined with BRTX (mean dose 50.2 +/- 13.2 Gy, dose rate of 0.3-0.4 Gy/hr)
Number of subjects: 83
Study 9465587 — intervention group
Group type: COMPARATOR
Intervention: Standard EBRT (mean dose 51.5 +/- 12.4 Gy in 2.0 Gy fractions)
Number of subjects: 83
Study 9465587 — intervention group
Group type: EXPERIMENTAL
Intervention: EBRT combined with BRTX for glioblastoma multiforme
Number of subjects: 83
Study 9465587 — intervention group
Group type: EXPERIMENTAL
Intervention: BRTX as an adjuvant to EBRT
Number of subjects: 83
Study 7682427 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin, methotrexate and bleomycin (EMB)
Number of subjects: 53
Study 7682427 — intervention group
Group type: COMPARATOR
Intervention: cisplatin-methotrexate-bleomycin (DMB)
Number of subjects: 53
Study 3332129 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 Gy single dose TBI (n = 27)
Number of subjects: 75
Study 3332129 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.2 Gy single dose TBI (n = 22)
Number of subjects: 75
Study 3332129 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 x 2 Gy fractionated TBI (n = 26)
Number of subjects: 75
Study 3332129 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.2 Gy single dose TBI
Number of subjects: 75
Study 3332129 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.2 Gy single dose TBI and 10 Gy single dose TBI
Number of subjects: 75
Study 3332129 — intervention group
Group type: COMPARATOR
Intervention: 6 x 2 Gy fractionated TBI
Number of subjects: 75
Study 29069383 — intervention group
Group type: COMPARATOR
Intervention: Tooth-borne (TB) rapid maxillary expansion (RME)
Number of subjects: 40
Study 29069383 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-bone-borne (TBB) rapid maxillary expansion (RME)
Number of subjects: 40
Study 27096580 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (45 min, cycle ergometer, 50% of peak oxygen uptake)
Number of subjects: 9
Study 27096580 — intervention group
Group type: COMPARATOR
Intervention: Rest (seated, 45 min)
Number of subjects: 9
Study 24767551 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple antibiotic paste (metronidazole, ciprofloxacin, and minocycline) (TAP)
Number of subjects: 23
Study 24767551 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of calcium hydroxide and 2% chlorhexidine gel (CHP)
Number of subjects: 23
Study 23297563 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion over Zusanli (ST 36) for 20 min
Number of subjects: 30
Study 23297563 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion over Hegu (LI 4) for 20 min
Number of subjects: 30
Study 20056686 — intervention group
Group type: COMPARATOR
Intervention: Kaletra tablets (400 mg of lopinavir)
Number of subjects: 12
Study 20056686 — intervention group
Group type: COMPARATOR
Intervention: Lopimune granules (400 mg of lopinavir)
Number of subjects: 12
Study 20056686 — intervention group
Group type: COMPARATOR
Intervention: Lopimune paediatric tablets (400 mg of lopinavir)
Number of subjects: 12
Study 20056686 — intervention group
Group type: COMPARATOR
Intervention: Lopimune granules with food
Number of subjects: 12
Study 20056686 — intervention group
Group type: COMPARATOR
Intervention: Kaletra solution with food
Number of subjects: 12
Study 20056686 — intervention group
Group type: COMPARATOR
Intervention: Lopimune formulations
Number of subjects: 12
Study 18228124 — intervention group
Group type: EXPERIMENTAL
Intervention: CDC language on condom effectiveness
Number of subjects: 1194
Study 18228124 — intervention group
Group type: COMPARATOR
Intervention: Proposed FDA label
Number of subjects: 1194
Study 18228124 — intervention group
Group type: COMPARATOR
Intervention: Current label on condom packaging
Number of subjects: 1194
Study 15630410 — intervention group
Group type: EXPERIMENTAL
Intervention: val66met SNP (allele G) in schizophrenia group
Number of subjects: 584
Study 15630410 — intervention group
Group type: EXPERIMENTAL
Intervention: haplotype analysis of val/met SNP and dinucleotide repeat polymorphism
Number of subjects: 584
Study 15630410 — intervention group
Group type: COMPARATOR
Intervention: Control group (350 individuals)
Number of subjects: 584
Study 14738367 — intervention group
Group type: EXPERIMENTAL
Intervention: Video of appropriate throwing mechanics
Number of subjects: 55
Study 14738367 — intervention group
Group type: EXPERIMENTAL
Intervention: Text information describing appropriate mechanics of the overhand throw
Number of subjects: 55
Study 14738367 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of video and text information
Number of subjects: 55
Study 14738367 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 55
Study 10370680 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha administered 6 million units subcutaneously daily for 2 weeks, then thrice weekly for 6 months (Group A)
Number of subjects: 154
Study 10370680 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha administered 6 million units thrice weekly for 6 months (Group B)
Number of subjects: 154
Study 10370680 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha administered 6 million units subcutaneously daily for 2 weeks, then thrice weekly for 6 months (Group A) in intermediate viral load group
Number of subjects: 154
Study 10370680 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha administered 6 million units thrice weekly for 6 months (Group B) in intermediate viral load group
Number of subjects: 154
Study 10370680 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha administered 6 million units subcutaneously daily for 2 weeks, then thrice weekly for 6 months (Group A) in genotype 2 patients
Number of subjects: 154
Study 10370680 — intervention group
Group type: COMPARATOR
Intervention: Interferon-alpha administered 6 million units thrice weekly for 6 months (Group B) in genotype 2 patients
Number of subjects: 154
Study 8900905 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholic acid (500 mg/day for 4 weeks)
Number of subjects: 23
Study 8900905 — intervention group
Group type: EXPERIMENTAL
Intervention: Chenodeoxycholic acid (500 mg/day for 4 weeks)
Number of subjects: 23
Study 8900905 — intervention group
Group type: EXPERIMENTAL
Intervention: Deoxycholic acid (500 mg/day for 4 weeks)
Number of subjects: 23
Study 8900905 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin (1 g/day for 2 weeks)
Number of subjects: 23
Study 1807272 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled toxic chemicals (phenol <0.0025 ppm, ethyl alcohol <0.5 ppm, formaldehyde <0.2 ppm, chlorine <0.3 ppm, pesticide 2,3-D <0.0034 ppm)
Number of subjects: 50
Study 1807272 — intervention group
Group type: COMPARATOR
Intervention: Placebos (water or saline)
Number of subjects: 50
Study 6637574 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol (Omnipaque)
Number of subjects: 42
Study 6637574 — intervention group
Group type: COMPARATOR
Intervention: metrizoate (Isopaque)
Number of subjects: 42
Study 31146326 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydration
Number of subjects: 12
Study 31146326 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehydration
Number of subjects: 12
Study 29278526 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped learning
Number of subjects: 108
Study 29278526 — intervention group
Group type: COMPARATOR
Intervention: Conventional learning
Number of subjects: 108
Study 26211687 — intervention group
Group type: EXPERIMENTAL
Intervention: ProArgin(™) paste
Number of subjects: 56
Study 26211687 — intervention group
Group type: COMPARATOR
Intervention: Gluma(®) Desensitizer
Number of subjects: 56
Study 26211687 — intervention group
Group type: COMPARATOR
Intervention: NovaMin(®) paste
Number of subjects: 56
Study 24963110 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated closed-loop insulin delivery
Number of subjects: 17
Study 24963110 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented insulin pump therapy (SAP)
Number of subjects: 17
Study 22554052 — intervention group
Group type: EXPERIMENTAL
Intervention: Active video game intervention (PlayStation EyeToy™)
Number of subjects: 322
Study 19528843 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonlinear periodized (NLP) resistance training
Number of subjects: 27
Study 19528843 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear periodized (LP) resistance training
Number of subjects: 27
Study 19528843 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonperiodized (NP) resistance training
Number of subjects: 27
Study 17487114 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound gel
Number of subjects: 346
Study 17487114 — intervention group
Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 346
Study 15600245 — intervention group
Group type: EXPERIMENTAL
Intervention: TMC-114
Number of subjects: 0
Study 11443021 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication review
Number of subjects: 332
Study 11443021 — intervention group
Group type: COMPARATOR
Intervention: Normal care (Control)
Number of subjects: 332
Study 9498972 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (Azmacort) oral inhaler 4 puffs twice daily (800 microg daily) for 7 days
Number of subjects: 20
Study 9498972 — intervention group
Group type: EXPERIMENTAL
Intervention: IV hydrocortisone (3 microg/kg/min) as a 14-h continuous infusion
Number of subjects: 20
Study 9498972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7702445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg/d
Number of subjects: 324
Study 7702445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 100 mg/d
Number of subjects: 324
Study 7702445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 200 mg/d
Number of subjects: 324
Study 7702445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 2565723 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-chest position
Number of subjects: 20
Study 2565723 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 20
Study 2565723 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall emesis episodes
Number of subjects: 20
Study 970609 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-0% etidocaine with 1/200,000 adrenaline
Number of subjects: 0
Study 970609 — intervention group
Group type: COMPARATOR
Intervention: 1-5% lignocaine with 1/200,000 adrenaline
Number of subjects: 0
Study 31522376 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal self-sampling for HPV
Number of subjects: 43
Study 31017076 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving intervention (n = 89)
Number of subjects: 173
Study 31017076 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group (n = 84)
Number of subjects: 173
Study 29192798 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition education and fruit and vegetable (F/V) supplementation
Number of subjects: 0
Study 26991958 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-dorsal injection
Number of subjects: 86
Study 26991958 — intervention group
Group type: COMPARATOR
Intervention: Single-volar injection
Number of subjects: 86
Study 25547580 — intervention group
Group type: EXPERIMENTAL
Intervention: Head hypsokinesis 10° group (15 eyes)
Number of subjects: 54
Study 25547580 — intervention group
Group type: EXPERIMENTAL
Intervention: Head hypsokinesis 20° group (17 eyes)
Number of subjects: 54
Study 25547580 — intervention group
Group type: EXPERIMENTAL
Intervention: Head hypsokinesis 30° group (17 eyes)
Number of subjects: 54
Study 25547580 — intervention group
Group type: EXPERIMENTAL
Intervention: Head hypsokinesis 40° group (16 eyes)
Number of subjects: 54
Study 25547580 — intervention group
Group type: COMPARATOR
Intervention: Comparison of intubation success rates
Number of subjects: 54
Study 25547580 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful intubation cases
Number of subjects: 54
Study 25547580 — intervention group
Group type: EXPERIMENTAL
Intervention: Angle θ of successful intubation cases
Number of subjects: 54
Study 25547580 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan after successful intubation
Number of subjects: 54
Study 22863660 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD-TDV (3 injections at months 0, 6, and 12)
Number of subjects: 298
Study 22863660 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 injections at months 0 and 6) or pneumococcal polysaccharide vaccine (month 12)
Number of subjects: 298
Study 22863660 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD-TDV
Number of subjects: 298
Study 22863660 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo or pneumococcal polysaccharide vaccine)
Number of subjects: 298
Study 20060105 — intervention group
Group type: EXPERIMENTAL
Intervention: Real high-frequency repetitive transcranial magnetic stimulation (rTMS) to the left DLPFC
Number of subjects: 38
Study 20060105 — intervention group
Group type: COMPARATOR
Intervention: Sham high-frequency repetitive transcranial magnetic stimulation (rTMS) to the left DLPFC
Number of subjects: 38
Study 18775200 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg/d) with extended-release oxybutynin (10 mg/d)
Number of subjects: 420
Study 18775200 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin (0.4 mg/d) alone (Control)
Number of subjects: 420
Study 15969702 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment strategy involving a screening survey and informational meetings with RO representatives.
Number of subjects: 100
Study 15969702 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligible ROs
Number of subjects: 100
Study 15969702 — intervention group
Group type: EXPERIMENTAL
Intervention: Size of the RO and the number of years that the religious leader had been with the RO.
Number of subjects: 100
Study 11268029 — intervention group
Group type: EXPERIMENTAL
Intervention: Index of polyneuropathy (IPN)
Number of subjects: 38
Study 11268029 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve conduction studies
Number of subjects: 38
Study 11268029 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathy symptom score (NSS)
Number of subjects: 38
Study 11268029 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropathy disability score (NDS)
Number of subjects: 38
Study 9626637 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g/day)
Number of subjects: 31
Study 9626637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8534380 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium nitrate/copolymer/pyrophosphate dentifrice
Number of subjects: 67
Study 8534380 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 67
Study 2896581 — intervention group
Group type: EXPERIMENTAL
Intervention: HRP112 (depot‐medroxyprogesterone acetate, 25mg and estradiol cypionate, 5 mg)
Number of subjects: 2328
Study 2896581 — intervention group
Group type: COMPARATOR
Intervention: HRP102 (norethisterone enantate, 50 mg and estradiol valerate, 5 mg)
Number of subjects: 2328
Study 2896581 — intervention group
Group type: EXPERIMENTAL
Intervention: HRP112
Number of subjects: 2328
Study 2896581 — intervention group
Group type: COMPARATOR
Intervention: HRP102
Number of subjects: 2328
Study 2350777 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis (group T, n = 17)
Number of subjects: 35
Study 2350777 — intervention group
Group type: COMPARATOR
Intervention: Control (group K, n = 18)
Number of subjects: 35
Study 2350777 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis (group T)
Number of subjects: 35
Study 2350777 — intervention group
Group type: COMPARATOR
Intervention: Control (group K)
Number of subjects: 35
Study 4392540 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 4392540 — intervention group
Group type: EXPERIMENTAL
Intervention: MJ 1999
Number of subjects: 0
Study 31954199 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Glucose Tolerance Test (OGTT) - 300 kcal
Number of subjects: 64
Study 31954199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed Meal Tolerance Test - 1130 kcal
Number of subjects: 64
Study 31954199 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting P1NP
Number of subjects: 64
Study 31954199 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal-induced suppression of P1NP
Number of subjects: 64
Study 30659702 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly prompted BP self-monitoring and healthy behavior text messages
Number of subjects: 104
Study 30659702 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 104
Study 28335835 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis with tenecteplase
Number of subjects: 709
Study 28335835 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 709
Study 25559659 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 1,200 mg starting two days before the operation, in addition to isonitrogenous and isocaloric total parenteral nutrition.
Number of subjects: 33
Study 25559659 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 33
Study 25559659 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 33
Study 23321948 — intervention group
Group type: EXPERIMENTAL
Intervention: Tagged vaginal gel (4 mL of tenofovir placebo gel with 15 mg 2‐pentyl acetate)
Number of subjects: 25
Study 23321948 — intervention group
Group type: EXPERIMENTAL
Intervention: Tagged condom (with 15 mg 2‐butyl acetate)
Number of subjects: 25
Study 23321948 — intervention group
Group type: EXPERIMENTAL
Intervention: Tagged products
Number of subjects: 25
Study 20589903 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A)
Number of subjects: 20
Study 20589903 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 20
Study 19526810 — intervention group
Group type: EXPERIMENTAL
Intervention: Point injection of red-sage-root (Danshen) in 5 ml normal saline, 2.5 ml per point, 3 times a week for 6 months
Number of subjects: 62
Study 19526810 — intervention group
Group type: COMPARATOR
Intervention: Core decompression (CDC) surgery
Number of subjects: 62
Study 17937531 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial concern severity
Number of subjects: 120
Study 17937531 — intervention group
Group type: EXPERIMENTAL
Intervention: Expression of three severe concerns immediately after trauma
Number of subjects: 120
Study 17937531 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical health concerns
Number of subjects: 120
Study 17937531 — intervention group
Group type: EXPERIMENTAL
Intervention: Work and finance concerns
Number of subjects: 120
Study 17937531 — intervention group
Group type: EXPERIMENTAL
Intervention: Social concerns
Number of subjects: 120
Study 17937531 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological concerns
Number of subjects: 120
Study 17937531 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical concerns
Number of subjects: 120
Study 17937531 — intervention group
Group type: EXPERIMENTAL
Intervention: Legal concerns
Number of subjects: 120
Study 15133849 — intervention group
Group type: EXPERIMENTAL
Intervention: Hejie decoction (HJD)
Number of subjects: 65
Study 15133849 — intervention group
Group type: COMPARATOR
Intervention: Routine Western medicine (Control)
Number of subjects: 65
Study 11481387 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial PSA screening (first round)
Number of subjects: 4491
Study 11481387 — intervention group
Group type: EXPERIMENTAL
Intervention: Second PSA screening (four years later)
Number of subjects: 4491
Study 9504446 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg/diltiazem ER 120 mg (E5/D120)
Number of subjects: 891
Study 9504446 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg/diltiazem ER 180 mg (E5/D180)
Number of subjects: 891
Study 9504446 — intervention group
Group type: COMPARATOR
Intervention: All active treatments
Number of subjects: 891
Study 9504446 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed combination of enalapril/diltiazem ER (E/D)
Number of subjects: 891
Study 8002149 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole, 100 mg daily for 6 weeks
Number of subjects: 35
Study 8002149 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin, 500 mg daily for 6 weeks
Number of subjects: 35
Study 3400564 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg three times a day in 10 patients and four times a day in 9 patients)
Number of subjects: 19
Study 3400564 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (after 14 days of diltiazem alone)
Number of subjects: 19
Study 3400564 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (0.125 mg/day in 2 patients and 0.250 mg/day in 17 patients)
Number of subjects: 19
Study 31288666 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy
Number of subjects: 0